Comparing two PET tracers in ER-positive breast cancer
Part of Cancer, Skin clinical trials.
This trial compares two types of PET scans to see which one better detects ER-positive breast cancer. The results could help doctors choose the best scan for tracking your cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman with ER-positive breast cancer confirmed by a biopsy.
- Your cancer is either locally advanced (large tumor or spread to lymph nodes) or has come back or spread to other parts of the body.
- You are scheduled for a standard FDG PET scan as part of your cancer staging.
- You are 18 years or older and not pregnant.
- You do not have any metal implants, severe claustrophobia, or other conditions that prevent an MRI.
- You do not have a chronic inflammatory disease like rheumatoid arthritis or severe liver or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging agent (18F-FAPI-04) for PET scans to see if it can better detect breast cancer or its spread. It may help doctors find tumors more clearly.
This early study tests a special PET scan (a type of imaging) to look at newly diagnosed ER-positive breast cancer. The goal is to see how well the scan can detect and measure cancer, which may help guide care.
This trial uses a special imaging scan called 18F-FES PET/CT to help doctors plan treatment and check how well it works for breast cancer that is ER-positive (meaning the cancer cells grow in response to estrogen). It may help improve treatment choices and monitoring.
This trial tests whether a special PET/CT scan using a tracer called FAPI can better detect if breast cancer has spread to lymph nodes under the arm after neoadjuvant treatment. If successful, it could guide more precise surgery and avoid unnecessary lymph node removal.
This study tests a new imaging method using a special tracer and PET/MRI scans to better see breast cancer. It may help doctors plan your treatment more precisely.
This study compares two special PET/CT scan tracers—68Ga-FAPI-LM3 and 18F-FDG—to see how well they detect cancer that shows FAP or SSTR2 signals. It may help doctors choose better imaging to find or assess certain tumors.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.